S

SPIEZIA A. L.

Last name: SPIEZIA A. L.

2024 (v1)

Publication

Metadata-only

NEDA-3 achievement in early highly active relapsing remitting multiple sclerosis patients treated with Ocrelizumab or Natalizumab

Signoriello E. Signori A. Lus G.

Background: in the early stages of Multiple Sclerosis (MS), initiating high-efficacy disease-modifying therapy (HE DMTs) may represent an optimal strategy for delaying neurological damage and long-term disease progression, especially in highly active MS patients (HAMS). Natalizumab (NAT) and Ocrelizumab (OCR) are recognized as HE DMTs with...

Uploaded on: September 24, 2024